Immune checkpoint blockade (ICB) therapies have revolutionized cancer treatment, yet many tumors remain resistant. Now, ...

Dr. Vincent Ma discussed the most recent and notable treatment updates for patients with high-risk and advanced melanoma.

Liver cancer is a malignant tumor characterized by high incidence and mortality rates worldwide. According to the report by the World Health Organization, ...

Immune checkpoints are regulatory proteins that prevent the immune system from attacking healthy tissues. Some cancer cells ...

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq ...

During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient ...

A study led by Prof. Liang Xingjie's team from the National Center for Nanoscience and Technology of the Chinese Academy of ...

A Scots teacher who was told it was "highly unlikely" she had cancer because "young people have lumpy boobs" was later ...

A real-world study showed a 49% response rate with Amtagvi in patients with advanced melanoma, supporting earlier use after immunotherapy.

ARPA-H, part of HHS, has earmarked up to $142 million for 10 research projects building the tools, data, and infrastructure needed to tackle treatment resistance.

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new treatment options.

A glucose-sensitive nanovaccine delivers CRISPR to tumors, silences immune-suppressing genes, and activates a targeted immune response against cancer.